Barbara Rogers President & CEO National Emphysema/COPD Association.
COPD - Association pulmonaire du Québec · COPD involves two respiratory problems, i.e. chronic...
1
VENTOLIN ® MDI 100 µg salbutamol VENTOLIN ® DISKUS ® 200 µg salbutamol AIROMIR ® MDI 100 µg salbutamol Short-acting bronchodilators ONBREZ ® BREEZHALER ® 75 µg indacaterol maleate SEREVENT ® DISKUS ® 50 µg salmeterol xinafoate OXEZE ® TURBUHALER ® 6 µg • 12 µg formoterol fumarate Long-acting bronchodilators SEEBRI ® BREEZHALER ® 50 μg glycopyrronium SPIRIVA ® RESPIMAT ® 2,5 μg tiotropium bromide INCRUSE ® ELLIPTA ® 62,5 μg umeclidinium TUDORZA ® GENUAIR ® 400 μg aclidinium bromide SPIRIVA ® HANDIHALER ® 18 μg tiotropium bromide Long-acting muscarinic antagonist COMBIVENT ® RESPIMAT ® 20/100 μg Ipratropium bromide and salbutamol Combination medication (short-acting muscarinic antagonist and short-acting bronchodilator) ATROVENT ® MDI 20 µg ipratropium bromide Short-acting muscarinic antagonist COPD involves two respiratory problems, i.e. chronic bronchitis and emphysema. These two conditions cause a gradual obstruction of the respiratory tract. Afflicted individuals may suffer from either of the two illnesses or both at the same time. Sufferers may exhibit one or several of the following symptoms: •Shortness of breath •Chronic cough •Secretions (mucus) Chronic bronchitis is characterized by permanent bronchial inflamma- tion and excessive production of mucus, which hampers the flow of air to the lungs. Emphysema affects the alveoli of the lungs. It causes dilation of the alveoli and destruction of the alveolar walls. The air remains trapped in the damaged alveoli, thus making it difficult to breathe. Gaseous exchanges are also affected by the destruction of the alveolar tissue. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) SIGNS AND SYMPTOMS EMPHYSEMA CHRONIC BRONCHITIS INHALATION CHAMBER Did you know that inhalers used without an inhalation chamber propel only 10% of the medication into the lungs and that almost 80% of the medication is simply deposited in the mouth? All inhalers should be used with an inhalation chamber. As a result, you will: •Optimize the administration of the drug (better deposition, better synchronization and simpler technique); •Reduce the side effects of certain drugs. Selected list of controllers BRICANYL ® TURBUHALER ® 0.5 mg terbutaline sulfate Normal airway Normal airway Inflammation Mucus Damaged alveoli Chronic bronchitis Emphysème FLOVENT ® MDI 50 µg • 125 µg 250 µg fluticasone propionate PULMICORT ® TURBUHALER ® 100 µg • 200 µg 400 µg budesonide Inhaled corticosteroids FLOVENT ® DISKUS ® 50 µg • 100 µg 250 µg • 500 µg fluticasone propionate BREO ® ELLIPTA ® 100/25 µg fluticasone furoate and vilanterol ADVAIR ® MDI 125/25 µg 250/25 µg fluticasone propionate and salmeterol SYMBICORT ® TURBUHALER ® 100/6 µg • 200/6 µg budesonide and formoterol fumarate Combination medications (inhaled corticosteroids and long-acting bronchodilators) ADVAIR ® DISKUS ® 100/50 µg • 250/50 µg 500/50 µg fluticasone propionate and salmeterol ANORO ® ELLIPTA ® 62.5/25 µg umeclidinium and vilanterol ULTIBRO ® BREEZHALER ® 50/110 µg glycopyrronium and indacaterol maleate DUAKLIR ® GENUAIR ® 400/12 μg aclidinium bromide and formoterol fumarate INSPIOLTO ® RESPIMAT ® 2,5/2,5 μg tiotropium bromide and olodaterol hydrochloride Combination medications (Long-acting muscarinic antagonist and long-acting bronchodilators) •Increasingly frequent respiratory infections and slower recovery •Fatigue •Reduced ability to pursue everyday activities COPD MEDICATIONS CHART Selected list of relievers Head office : 6070 Sherbrooke Street East, office 104 Montreal (Quebec) H1N 1C1 www.pq.lung.ca
-
Upload
phamkhuong -
Category
Documents
-
view
218 -
download
0
Transcript of COPD - Association pulmonaire du Québec · COPD involves two respiratory problems, i.e. chronic...
VENTOLIN® MDI
100 µgsalbutamol
VENTOLIN®
DISKUS®
200 µgsalbutamol
AIROMIR®
MDI
100 µgsalbutamol
Short-acting bronchodilators
ONBREZ®
BREEZHALER®
75 µgindacaterol maleate
SEREVENT® DISKUS®
50 µgsalmeterol xinafoate
OXEZE® TURBUHALER®
6 µg • 12 µgformoterol fumarate
Long-acting bronchodilators
SEEBRI® BREEZHALER®
50 μg glycopyrronium
SPIRIVA® RESPIMAT®
2,5 μg tiotropium bromide
INCRUSE® ELLIPTA®
62,5 μg umeclidinium
TUDORZA® GENUAIR®
400 μgaclidinium bromide
SPIRIVA®
HANDIHALER®
18 μgtiotropium bromide
Long-acting muscarinic antagonist
COMBIVENT®
RESPIMAT®
20/100 μgIpratropium bromide and salbutamol
Combination medication (short-acting muscarinic antagonist and short-acting bronchodilator)
ATROVENT ®
MDI
20 µgipratropium bromide
Short-acting muscarinic antagonist
COPD involves two respiratory problems, i.e. chronic bronchitis and emphysema. These two conditions cause a gradual obstruction of the respiratory tract. Afflicted individuals may suffer from either of the two illnesses or both at the same time.
Sufferers may exhibit one or several of the following symptoms:
•Shortness of breath•Chronic cough•Secretions (mucus)
Chronic bronchitis is characterized by permanent bronchial inflamma-tion and excessive production of mucus, which hampers the flow of air to the lungs.
Emphysema affects the alveoli of the lungs. It causes dilation of the alveoli and destruction of the alveolar walls. The air remains trapped in the damaged alveoli, thus making it difficult to breathe. Gaseous exchanges are also affected by the destruction of the alveolar tissue.
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
SIGNS AND SYMPTOMS
EMPHYSEMACHRONIC BRONCHITIS
INHALATION CHAMBER
Did you know that inhalers used without an inhalation chamber propel only 10% of the medication into the lungs and that almost 80% of the medication is simply deposited in the mouth? All inhalers should be used with an inhalation chamber. As a result, you will:•Optimize the administration of the drug (better deposition, better synchronization and simpler technique);•Reduce the side effects of certain drugs.
Selected list of controllers
BRICANYL®
TURBUHALER®
0.5 mgterbutaline sulfate
Normal airway Normal airway
Inflammation
Mucus
Damaged alveoli
Chronic bronchitis Emphysème
FLOVENT® MDI
50 µg • 125 µg 250 µgfluticasone propionate
PULMICORT® TURBUHALER®
100 µg • 200 µg 400 µgbudesonide
Inhaled corticosteroids
FLOVENT® DISKUS®
50 µg • 100 µg 250 µg • 500 µgfluticasone propionate
BREO® ELLIPTA®
100/25 µgfluticasone furoate and vilanterol
ADVAIR®
MDI
125/25 µg 250/25 µgfluticasone propionate and salmeterol
SYMBICORT®
TURBUHALER®
100/6 µg • 200/6 µgbudesonide and formoterol fumarate
Combination medications (inhaled corticosteroids and long-acting bronchodilators)
ADVAIR® DISKUS®
100/50 µg • 250/50 µg 500/50 µgfluticasone propionate and salmeterol
ANORO®
ELLIPTA®
62.5/25 µgumeclidinium and vilanterol
ULTIBRO® BREEZHALER®
50/110 µgglycopyrronium and indacaterol maleate
DUAKLIR® GENUAIR®
400/12 μgaclidinium bromide and formoterol fumarate
INSPIOLTO® RESPIMAT®
2,5/2,5 μgtiotropium bromide and olodaterol hydrochloride
Combination medications (Long-acting muscarinic antagonist and long-acting bronchodilators)
•Increasingly frequent respiratory infections and slower recovery•Fatigue•Reduced ability to pursue everyday activities
COPDMEDICATIONS CHART
Selected list of relievers
Head office : 6070 Sherbrooke Street East, office 104Montreal (Quebec) H1N 1C1www.pq.lung.ca
